<DOC>
	<DOCNO>NCT00004865</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody cetuximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining monoclonal antibody therapy chemotherapy may kill tumor cell . PURPOSE : Phase II trial study effectiveness cetuximab plus cisplatin treating patient metastatic recurrent cancer head neck respond previous cisplatin-based chemotherapy .</brief_summary>
	<brief_title>Cetuximab Plus Cisplatin Treating Patients With Metastatic Recurrent Cancer Head Neck That Has Not Responded Cisplatin Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , duration response , survival patient metastatic recurrent squamous cell carcinoma head neck treat cetuximab cisplatin failure initial cisplatin-based chemotherapy regimen . II . Determine efficacy , safety , toxicity regimen patient . III . Assess quality life patient treat regimen . OUTLINE : This multicenter study . Part I ( course 1 2 ) : Patients assign 1 2 treatment group base prior cisplatin-based chemotherapy regimen : Group 1 ( prior cisplatin paclitaxel ) : Patients receive cisplatin IV 1 hour day 1 fluorouracil IV continuously day 1-4 . Group 2 ( prior cisplatin fluorouracil ) : Patients receive cisplatin IV 1 hour paclitaxel IV 3 hour day 1 . Both group : Treatment repeat every 3 week 2 course . Patients achieve partial complete response completion course 2 take study . Patients stable disease disease progression completion course 2 proceed part II study . Part II ( course 3-6 ) : Patients stratify response initial cisplatin-based chemotherapy regimen ( stable disease vs disease progression ) . Patients receive test dose cetuximab IV 10 minute day 1 . Patients experience grade 4 anaphylactic reaction receive load dose cetuximab IV 2 hour begin 30 minute completion test dose . Patients receive cisplatin IV 1 hour begin 1 hour completion cetuximab infusion day 1 . Patients receive maintenance cetuximab IV 1 hour day 8 . Maintenance cetuximab repeat weekly . Combination treatment repeat every 3 week maximum 4 course . Patients stable respond disease completion course 6 may continue receive cetuximab alone absence disease progression discretion protocol investigator sponsor . Quality life assess course 1 , completion course 2 , 4 , 6 , 4 week completion study . Patients follow 4 week . PROJECTED ACCRUAL : Approximately 175 patient accrue study within 8 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic recurrent squamous cell carcinoma head neck Failure respond initial treatment cisplatin paclitaxel cisplatin fluorouracil Bidimensionally measurable disease Sufficient tumor tissue available immunohistochemical determination epidermal growth factor receptor expression No meningeal CNS involvement tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 WBC least 3,000/mm3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 2.5 time ULN AST ALT great 2.5 time ULN Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 60 mL/min Cardiovascular : No history clinically significant cardiac disease , serious arrhythmia , significant conduction abnormality Neurologic : No uncontrolled seizure disorder No active neurologic disease No neuropathy great grade 1 Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No malignancy within past 3 year except basal cell skin cancer preinvasive carcinoma cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior murine monoclonal antibody therapy cetuximab Chemotherapy : See Disease Characteristics More 1 year since prior chemotherapy recover Cumulative total dose prior platinum therapy great 200 mg/m2 No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 2 month since prior radiotherapy ( 1 month disease progression occur radiotherapy ) No concurrent radiotherapy Surgery : At least 2 month since prior surgery except diagnostic biopsy Other : At least 1 month since prior investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>